Trexquant Investment’s Stemline Therapeutics, Inc. STML Stock Holding History

Trexquant Investment’s Portfolio STML Stock Details STML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-30,738	Closed	-$395K	–	1281
2019 Q1	$395K	Buy	30,738 +15,557	+102%	+$176K	0.03%	659
2018 Q4	$144K	Buy	+15,181	New	+$197K	0.01%	960
2018 Q2	–	Sell	-15,181	Closed	-$232K	–	1379
2018 Q1	$232K	Sell	15,181 -8,792	-37%	-$137K	0.02%	911
2017 Q4	$374K	Buy	+23,973	New	+$321K	0.04%	637
2017 Q3	–	Sell	-33,017	Closed	-$304K	–	1141
2017 Q2	$304K	Sell	33,017 -24,294	-42%	-$203K	0.08%	459
2017 Q1	$490K	Buy	+57,311	New	+$522K	0.06%	549

Other funds holding STML

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Trexquant Investment's STML Position: Q2 2019 in Review

Trexquant Investment sold out of Stemline Therapeutics, Inc. (STML) in Q2 2019, closing a stake of 30,738 shares — an estimated $395K sold.

Trexquant Investment first reported a position in STML in Q1 2017 and held it in 6 quarters. The position peaked at $490K in Q1 2017. 96 funds tracked by Wall St. Rank hold STML as of Q2 2019.

Trexquant Investment reported no remaining Stemline Therapeutics, Inc. position as of Q2 2019 after selling out during the quarter.
Trexquant Investment sold 30,738 Stemline Therapeutics, Inc. shares in Q2 2019, an estimated $395K.
Trexquant Investment first reported a position in Stemline Therapeutics, Inc. in Q1 2017 and held it in 6 quarters.
Trexquant Investment's Stemline Therapeutics, Inc. position peaked at $490K in Q1 2017.
96 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2019.

Based on Trexquant Investment's 13F filing for Q2 2019, filed 9 Aug 2019.